206 related articles for article (PubMed ID: 33023787)
1. Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer.
Chen TC; Jeng YM; Liang JT
J Formos Med Assoc; 2021 May; 120(5):1194-1201. PubMed ID: 33023787
[TBL] [Abstract][Full Text] [Related]
2. Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
Yu YL; Tseng WK; Liao CK; Yeh CY; Chen HH; Liu YH; Liaw YW; Fan CW
BMC Cancer; 2023 Sep; 23(1):900. PubMed ID: 37749535
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
[TBL] [Abstract][Full Text] [Related]
4. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.
Sasaki Y; Akasu T; Saito N; Kojima H; Matsuda K; Nakamori S; Komori K; Amagai K; Yamaguchi T; Ohue M; Nagashima K; Yamada Y
Cancer Sci; 2016 Jul; 107(7):1006-12. PubMed ID: 27089049
[TBL] [Abstract][Full Text] [Related]
6. Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients.
Liang SK; Wu CW; Chang CI; Keng LT; Lee MR; Wang JY; Ko JC; Liao WY; Chen KY; Ho CC; Shih JY; Yu CJ
Cancer Med; 2023 Sep; 12(17):17993-18004. PubMed ID: 37559409
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial.
Kato T; Ohashi Y; Nakazato H; Koike A; Saji S; Suzuki H; Takagi H; Nimura Y; Hasumi A; Baba S; Manabe T; Maruta M; Miura K; Yamaguchi A
Langenbecks Arch Surg; 2002 Mar; 386(8):575-81. PubMed ID: 11914933
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
Yen HH; Chen CN; Yeh CC; Lai IR
World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
10. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
11. Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial.
Fujii M; Takayama T; Kochi M
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1319-23. PubMed ID: 18512074
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy With UFT/LV
Ogawa H; Shiraishi T; Okada T; Miyamae Y; Motegi Y; Shirabe K; Saeki H
Anticancer Res; 2024 Feb; 44(2):805-814. PubMed ID: 38307591
[TBL] [Abstract][Full Text] [Related]
13. Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Sadahiro S; Morita S; Sasaki K; Sakamoto K; Ohge H; Takahashi T; Tsuchiya T; Sato T; Kondo K; Ogata Y; Masuko H; Baba H; Maeda K; Hamada M; Itabashi M; Nishimura G; Takahashi K; Ikeda M; Taguri M; Kodaira S
Clin Colorectal Cancer; 2015 Dec; 14(4):277-80. PubMed ID: 26068602
[TBL] [Abstract][Full Text] [Related]
14. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
Watanabe J; Sasaki S; Kusumoto T; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Yokota M; Tanaka C; Yamauchi J; Uetake H; Itabashi M; Takahashi K; Baba H; Kotake K; Boku N; Aiba K; Morita S; Takenaka N; Sugihara K
ESMO Open; 2021 Apr; 6(2):100077. PubMed ID: 33714860
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
[TBL] [Abstract][Full Text] [Related]
16. Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
Fujii M
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):55-60. PubMed ID: 10442363
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
18. A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Okuda H; Shimomura M; Ikeda S; Nakahara M; Miguchi M; Ishizaki Y; Saitoh Y; Toyota K; Sumitani D; Shimizu Y; Takakura Y; Shimizu W; Yoshimitsu M; Kodama S; Fujimori M; Oheda M; Kobayashi H; Ohdan H;
Cancer Chemother Pharmacol; 2023 Apr; 91(4):317-324. PubMed ID: 36947210
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).
Kosugi C; Koda K; Takiguchi N; Takaishi S; Miyauchi H; Hirayama N; Nomura Y; Kondo E; Kawasaki Y; Ozawa Y; Matsubara H
Int J Colorectal Dis; 2021 Aug; 36(8):1739-1749. PubMed ID: 33715077
[TBL] [Abstract][Full Text] [Related]
20. Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
Ishizuka M; Kubota K; Nemoto T; Shimoda M; Kato M; Iso Y; Tago K
Asian J Surg; 2016 Jul; 39(3):149-54. PubMed ID: 26123137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
